|
Session 79. Poster
Metabolic Complications of Antiretroviral Therapy
Below are images of the posters,
you can view an enlarged image of the poster by clicking the L,
C, or R above the image.
|
|
L -- C
-- R
641. Diagnosis and Prediction of
HIV Protease Inhibitor-Induced Lipodystrophy and Impaired Glucose
Tolerance.
|
|
L -- R
642. Frequency of Lipodystrophy and
Factors Associated with Glucose/Lipid Abnormalities in a Cohort
of 650 Patients Treated by Protease Inhibitors.
|
|
L -- C -- R
643. Effects of Protease Inhibitor
Use on Hyperglycemia and Hyperlipidemia: A Five Year Analysis.
|
|
L -- C
-- R
644. Prevalence and Risk Factors
for Hyperglycemia, Dyslipidemia, and Coronary Disease Among HIV-Infected
Patients on Initial Protease Inhibitor Therapy.
|
|
L -- R
645. Dyslipidemia and Insulin Resistance
in HIV-Infected Patients Treated with Reverse Transcriptase Inhibitors
Alone in Combination with Protease Inhibitors.
|
|
L -- C
-- R
646. Lipid Abnormalities and Body Composition Alterations
in Progressive Stages of HIV/HAART Associated Lipodystrophy Syndrome.
|
|
L -- R
647. Lipid Evaluation and Glucose Metabolism in HIV-1
Positive Patients Treated with Protease Inhibitors.
|
|
1 -- 2
-- 3 -- 4
648. Changes in Serum Cholesterol and Triglyceride
Levels in Patients Treated with Indinavir or NRTIs.
|
|
L -- R
649. The Prevalence of Hypertriglyceridemia in HIV
Infected Individuals Who Have Been Exposed to Various Antiretroviral
Drug Classes Since January 1996.
|
|
L -- R
650 High Prevalence of Impaired Glucose Tolerance
Prior to Initiating Protease Inhibitor Therapy.
|
|
L -- R
651. HIV-Related Truncal Obesity: A Comparison of
Physician and Patient Diagnoses in the SALSA Questionnaire.
|
|
L -- C
-- R
652. Lipodystrophy Index by Anthropometric Parameters:
An Approach to the Diagnosis of Lipodystrophy by Measurable Parameters
in Patients Taking Protease Inhibitors.
|
|
L -- R
653. A Syndrome of Lipodystrophy in Patients Receiving
a Stable Nucleoside-Analogue Therapy.
|
|
C
654. Lypodystrophy Syndrome in Patients on Reverse
Transciptase Inhibitors.
|
|
L -- C
-- R
655. Potential Adverse Experiences Associated with
Efavirenz in Adults.
|
|
L
656. Increased Morbidity from Severe Coronary Heart
Disease in HIV-Patients Receiving Protease Inhibitors.
|
|
L --C
-- R
657. Do Protease Inhibitors Increase the Risk for
Coronary Heart Disease Among HIV Positive Patients?
|
|
L -- R
658. No Association Observed Between Indinavir Therapy
for HIV/AIDS and Myocardial Infarction in Four Clinical Trials with
2,825 Subjects.
|
